STOCK TITAN

Pacific Biosciences of California Inc - PACB STOCK NEWS

Welcome to our dedicated news page for Pacific Biosciences of California (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosciences of California.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pacific Biosciences of California's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pacific Biosciences of California's position in the market.

Rhea-AI Summary
PacBio announces PacBio WGS Variant Pipeline, a standardized computational method for HiFi whole genome sequencing data analysis. The pipeline integrates PacBio and third-party tools, offering customers a complete solution for variant analysis. It streamlines the analysis process and provides access to alignment, variant calling, and genome annotation data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhea-AI Summary
PacBio announces PacBio Capital program for leasing sequencing systems, expanding access and reaching new markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
none
-
Rhea-AI Summary
PacBio announced that automation providers Hamilton, Integra, Revvity, and Tecan have created fully automated protocols to prepare samples for sequencing on Revio and Sequel II and IIe systems, aiming to make sample and library preparation easier for customers. The new Nanobind HT DNA extraction workflows will enable end-to-end automated workflows from sample to sequencing on PacBio HiFi long-read sequencing systems, allowing customers to easily scale to thousands of genomes per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PacBio (NASDAQ: PACB) Q2 2023 Financial Results: Revenue up 34% to $47.6M, Instrument Revenue Doubles, Net Loss Down, Acquisitions and Collaborations Announced
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.99%
Tags
Rhea-AI Summary
PacBio announces acquisition of Apton Biosystems to develop a high-throughput sequencer using Apton's technology and PacBio's Sequencing by Binding (SBB) chemistry. The acquisition is valued at approximately $110 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.99%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.99%
Tags
none
-
Rhea-AI Summary
PacBio (NASDAQ: PACB) will hold its quarterly conference call to discuss its second quarter 2023 financial results on August 2, 2023, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
none
Pacific Biosciences of California Inc

Nasdaq:PACB

PACB Rankings

PACB Stock Data

849.41M
266.44M
2.8%
101.74%
18.31%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States
Menlo Park

About PACB

pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.